Fig. 6

Impaired phagocytosis in ALS compared to HC MDMi. a Representative images of HC and ALS MDMi uptake of pHrodo-labelled E.coli particles (red). b Quantification of phagocytosis by pHrodo-labelled E.coli particles over 15 h using live imaging in HC and ALS. c Uptake of pHrodo-labelled E.coli particles in HC and ALS MDMi was quantified using area under the curve. d From (c), ALS MDMi were then categorised into disease subgroups. e Area of pHrodo-labelled E.coli particles normalised over cell number, quantified using IncuCyte ZOOM in-built software. f From (e), ALS MDMi were then categorised into disease subgroups. Area of pHrodo-labelled E.coli particles normalised against cell number, quantified using IncuCyte ZOOM in-built software. g Percentage of cells that contains phagocytose particles in HC and ALS MDMi. HC: n = 10, ALS: n = 11. n = 200 cells per patient or individual. h From (g), ALS MDMi were then categorised into disease subgroups. Percentage of cells that contain phagocytose particles in HC and ALS MDMi disease subgroups. HC: n = 10, ALS: n = 11. n = 200 cells per patient or individual. Formula as follows: (number of cells with particles/total number of cells)*100. Data were first tested for normality using Shapiro–Wilk test. Statistical analysis between two groups was performed using Student’s t test and between multiple groups using one-way ANOVA. For multiple testing, disease subgroups were compared between each other and to HC MDMi. All HC and ALS MDMi were differentiated for 14 days prior to downstream experiments. Values are mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Scale bars = 50 µm